🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

EUnetHTA 21 launched the second Open Call for applications from the pharmaceutical industry for five Joint Scientific Consultations (JSCs).The Open Call will remain open until 31 August 2022. The application form and further information can be found here: eunethta.eu/jsc/

EUnetHTA 21 is pleased to announce the publication of the deliverable D4.2 on Scoping Process. More information can be found here: eunethta.eu/d4-2/ Many thanks to all involved in the development of this deliverable! #eunethta #hta

EUnetHTA 21 announces that the public consultation for the draft deliverable D4.4 Endpoints is open until 01.11.2022, 23:59 CEST. General principles for public consultation can be found here: lnkd.in/eVitiYNK #eunethta #hta

Patient organisation input and healthcare professional input requested, until Nov. 14, 2022, for the Joint Clinical Assessment on a medical device for male patients with urinary symptoms associated with urethral stricture. eunethta.eu/get-involved/o…

EUnetHTA 21 is pleased to announce it has started a second JCA on a medical device. We are seeking for patient organisations and healthcare professional organisations to provide input. The deadline for input is 14-12-2022. More here: lnkd.in/egCR8Rk5

Today the twenty-third bilateral meeting between EMA & EUnetHTA took place. Key discussion topics on this occasion were patient relevant data for decision making, DARWIN EU and EMA funded registry-based studies. A report from the meeting will be published later.

EUnetHTA 21 is pleased to announce the publication of five deliverables: three practical guidelines (D4.3.1, D4.5, D4.6) and two guidances on templates (D5.1 and D5.2). More information can be found here: lnkd.in/eVWyPSX3 #hta #eunethta

EUnetHTA 21 is pleased to announce the publication of the deliverable  D4.4 on Endpoints.  More information can be found here: eunethta.eu/jointhtawork/  Many thanks to all involved in the development of the deliverables!

EUnetHTA 21 published the deliverable D7.1, which focusses on the guidance for the interaction between HTA bodies and Health Technology Developer during JCAs and JSCs, the process for a factual accuracy check and process to handle confidential information: lnkd.in/eVWyPSX3

EUnetHTA 21 is pleased to announce the publication of deliverable Deliverable D7.2/3 Guidance and template for the interaction with patient representative, healthcare professional and other experts. More information can be found here: lnkd.in/eVWyPSX3

EUnetHTA 21 is pleased to announce the publication of the deliverable D5.2 JCA Report Template and summary Template. This EUnetHTA 21 deliverable (D5.2) provides the Joint Clinical Assessment Report Template and Summary Template. More information here: eunethta.eu/d5-2/

The EUnetHTA 21 Consortium will cease operations on 16 September 2023 For more information, please read the article here: eunethta.eu/the-eunethta-2…

EUnetHTA 21 is pleased to announce the publication of the first JCA. The JCA was conducted on the medical device Optilumedrug-coated balloon (DCB), which is a urethral balloon that is precoated with an antiproliferative medicinal product (paclitaxel): eunethta.eu/d5-4/

The EUnetHTA 21 is pleased to announce the publication of the draft version of the D5.4 deliverable on medicinal JCA timelines. Please note, that this is a draft document and may be revised by August 2023. The draft document can be found here: lnkd.in/e-zkrvCs

We would like to announce that the EUnetHTA 21 deliverables ‘’D6.2.1 Briefing Document Template’’ and ‘’D6.4.1 External Guidance with EMA’' will be open for public consultation between until 31.07.2023, 23:59CEST. The draft deliverables can be found here lnkd.in/eVWyPSX3

HTDs will be able to apply for Parallel EMA/HTA body Scientific Advice from September 2023, when EUnetHTA 21 ceases to operate, until January 2025 when the Regulation on health technology assessment will become fully applicable. More information here: eunethta.eu/jsc/

The EUnetHTA 21 is pleased to announce the publication of the second Joint Clinical Assessment. The JCA was conducted on the medical device, Saluda Medical Evoke® Spinal Cord Stimulation (SCS) System, More information and the JCA report here: eunethta.eu/d5-4/

The EMA-EUnetHTA cooperation is coming to an end. A 13-year collaboration that helped medicine developers improve clinical research & become more efficient in generating evidence. Preparations continue for the implementation of the regulation on health technology assessment.